Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525282 | 0.84 | MAPK14 (0.56) | MAPTSMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL4468228 | 0.82 | MAPT (0.54) | MAPTSMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL3524926 | 0.81 | MAPK14 (0.46) | MAPTSMN1; SMN2MAPK14ROCK2ROCK1 | |
| SCHEMBL3523102 | 0.78 | GRIN1 (0.51) | MAPTMAPK14TP53ROCK2ROCK1 | |
| SCHEMBL3526877 | 0.78 | HPGD (0.57) | MAPTSMN1; SMN2MAPK14TP53ROCK2 | |
| SCHEMBL3525008 | 0.78 | MAPK14 (0.44) | MAPTSMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL3522065 | 0.77 | ROCK2 (0.48) | MAPTSMN1; SMN2MAPK14ROCK2ROCK1 | |
| SCHEMBL3526884 | 0.76 | MAPT (0.53) | MAPTSMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL3524971 | 0.73 | MAPK14 (0.53) | MAPTSMN1; SMN2POLBMAPK14ROCK2 | |
| SCHEMBL3526494 | 0.72 | MAPK14 (0.49) | MAPTSMN1; SMN2MAPK14ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPT 2576/4885SMN1; SMN2 912/4885POLB 1067/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPT 3038/4885SMN1; SMN2 746/4885POLB 726/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPT 2576/4885SMN1; SMN2 912/4885POLB 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.